() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Search for: "preveceutical"

PreveCeutical Partnership Leads to Two New Patent Filings

April 17, 2019 PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H) announces that the Company’s research collaboration with UniQuest and The University of Queensland (“UQ”) has led to the filing of two new patent applications for cyclic peptides and their use in pain management (the “Patent Applications”).
Read more

PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program

April 15th, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces the Company’s research team at the University of Queensland has filed an application to a local hospital’s Human Ethics Committee (the “Human Ethics Committee”) to acquire human nasal mucosal tissue (mucosal membrane) for use in the final phase of the cannabinoid-based, soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”).
Read more

PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model

April 10, 2019 PreveCeutical Medical Inc. (the “Company” or“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to announce further positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program (the “Peptide Program”), that is expected to enable the Company to generate Nature IdenticalTM peptide therapeutics intended for therapeuticapplications.
Read more

PreveCeutical Announces Default Judgment Against JCN Capital Corp.

PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has obtained a default judgement against JCN Capital Corp. (“JCN”) in connection with a Supreme Court of British Columbia action (the “Action”). The Action was brought by PreveCeutical in December 2018, against a group of defendants (the “Defendants”) for fraudulent misrepresentation, breach of contract, conspiracy, unjust enrichment and breach of duty of honest performance in connection with services that the Defendants failed to provide to PreveCeutical, and various consulting agreements and subscription agreements entered into between PreveCeutical and certain of the Defendants (see news release dated January 7, 2019).
Read more
Get $50 in free trades.